Neurocrine’s CAHtalyst pediatric data sharpens the case for CRENESSITY durability
Steroid reduction is the real test in pediatric CAH. Neurocrine’s CRENESSITY data now faces the durability, access and adoption question.
Why BioMarin’s VOXZOGO update matters ahead of hypochondroplasia Phase 3 data
VOXZOGO is no longer just a height story. BioMarin now needs long-term data to support a broader skeletal dysplasia strategy.